Praxis Precision Medicines, Inc. (PRAX) a Strong Buy, Per Wall Street Consensus
On January 12, Wedbush analyst Laura Chico lifted the price target on the stock to $95 from $83, citing the company’s recent public offering as the basis for the adjustment.









